Combination Pharmacotherapy for Smoking Cessation Among Methadone Patients

Completed · Phase 2

Conditions studied: Tobacco Use Disorder

In brief

The purpose of this pilot study is to examine the effects of combined pharmacotherapy (Zyban/NRT)/behavioral treatment on smoking cessation among methadone maintenance therapy patients.

Key facts

Study ID

NCT00060814

Run by

National Institute on Drug Abuse (NIDA)

People needed

28

Starts

2002-06-01

Expected to finish

2002-12-01

Last updated by the study team

2017-01-12

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients in long-term methadone maintenance treatment
• Patient smokes at least 10 cigarettes per day, are stable on their use of methadone (phase 2 or higher treatment), smoked for at least 1 year, be willing to participate for 6 months, and not have used bupropion or nicotine replacement therapy for 6 months

You may not qualify if…

• Patients who use prescription drug regimens that might affect methadone or bupropion metabolism
• Patients with cardiovascular disease, asthma, COPD
• Patients who are pregnant or breastfeeding
• Patients with regular use of alcohol, other illicit drugs, or other types of tobacco (chewing or pipe for example)

Where it is running

• University of Kansas Medical Center — Kansas City, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.